Financial Performance

SmartSweets founder Tara Bosch is back with Snackish, aiming to redefine chips. But her secret ingredient isn't just in the bag—it's the business model.

A BofA study reveals a seismic shift in wealth, where longer lives and a generational split over crypto are creating unprecedented financial complexity.

Tigera, the force behind Calico, launches Lynx to rein in chaotic AI agents, offering a kernel-deep control plane for a new era of enterprise security.

An Ohio school district is turning to AI to spot guns before shots are fired. But as algorithms watch the halls, what is the true cost of proactive security?

Sugar House Distillery is expanding its canned cocktails into Idaho, a strategic move testing if its 'grain-to-glass' ethos can capture a new market.

Thirty years ago, a US human rights report on a mining giant disappeared. A new investigation asks why, exposing a pattern of secrecy and human cost.

As employees flock to prediction markets, a new insider trading risk emerges. A new tech alliance aims to give firms the visibility they've been missing.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

XCharge's new C7 charger boasts record power, but its real test lies in winning public trust. A deep dive into the tech, strategy, and partnerships redefining speed.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

Glass House Brands follows a new playbook, splitting its business to chase a NYSE listing. Is this the key that unlocks institutional capital for the entire sector?

A new mid-year outlook reveals how geopolitical turmoil, the AI boom, and a renewed focus on sovereignty are reshaping investment strategies for a volatile H2 2026.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A new low-risk trial program for hybrid vehicles reveals China's pragmatic strategy to win over markets where pure EVs can't yet compete.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

New research reveals that custom 3D braces can actively correct spinal curves, not just prevent them from worsening. This paradigm shift in non-surgical care offers new hope.

SolarWinds appoints ex-USAF intelligence officer Justin Henkel as its new CISO, a strategic move to fortify its defenses and lead in the age of AI.

As gold and silver prices soar, Starcore International Mines upgrades to the OTCQX market. A strategic bid for US investors, but what's beneath the surface?

As AI becomes the new front door for travel, a new partnership gives hotels the tools to fight for their own narrative against the dominance of OTAs.